Instale la herramienta precio del oro!
Oro histórico precio de la plata
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
1982
1981
1980
1979
1978
1977
1976
1975
1974
1973
1972
1971
1970
1969
1968
|
2011/11/10
| USD / Onza | |
| Gold | 1766 | |
| Silver | 3371 |
Gold Oro histórico cuadro y el gráfico de precios
360 días gráfico ,
1 Ounce Gold=? USD
Silver Tabla de Precios Históricos de plata y el gráfico
360 días gráfico ,
1 Ounce Silver=? USD
Noticias de oro:
- FDA expands approval of Modernas RSV vaccine to some adults under age . . .
The U S Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease
- Moderna Receives U. S. FDA Approval for RSV Vaccine, mRESVIA, in Adults . . .
Expanded indication builds on existing U S FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA ACCESS Newswire June 12, 2025 Moderna, Inc (NASDAQ:MRNA) today announced that the U S Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD
- FDA expands approval for Modernas RSV vaccine - The Hill
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from
- US FDA Approves Expanded Use of Modernas RSV Vaccine for At-Risk Adults
The FDA approved mRESVIA in adults aged 60 or older last year, but with a lower efficacy label indicating the shot was 79% effective at preventing at least two symptoms of RSV, such as cough and
- Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger . . .
The expanded approval now includes individuals aged 18 to 59 who are at risk of RSV This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older
- FDA approves Moderna RSV vaccine use for people aged 18 to 59 - STAT
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they
- FDA expands Modernas RSV vaccine approval to at-risk adults - MSN
The U S Food and Drug Administration has approved Moderna’s (NASDAQ:MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 who are at
- Moderna wins FDA OK to widen use of RSV vaccine
The FDA cleared Moderna's RSV shot for use in certain adults between the ages of 18 and 59 on June 12, 2025 The Food and Drug Administration has approved wider use of Moderna’s respiratory syncytial virus vaccine in a boost for a company that’s been negatively impacted by the recent leadership changes atop U S public health agencies
- FDA Expands Moderna’s mRNA-1345 RSV Vaccine to Younger Adults
The FDA has expanded the approval of Moderna’s mRNA-1345 RSV vaccine to include people aged 18-59 years This comes after last year’s initial approval of the vaccine for seniors 60 years of age and older in prevention of lower respiratory tract disease caused by RSV infection 1 "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an
- Moderna Receives U. S. FDA Approval for RSV Vaccine, mRESVIA, in Adults . . .
This approval was supported by results from Moderna’s Phase 3 study (NCT06067230), which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions
|
|
precio del oro, comprar oro, vender oro ©2005-2009
|En tiempo real Tipo de Cambio
|disclaimer
|